Current and future role of biomarkers in Crohn’s disease risk assessment and treatment

References

• GascheCScholmerichJBrynskovJA simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998Inflamm Bowel Dis20006181510701144
   PubMed Web of Science ®Google Scholar
• ThiaKSandbornWHarmsenWZinmeisterAThe evolution of Crohn’s disease (CD) behavior in a population-based cohort [abstract 1135]Am J Gastroenterol2008103Suppl 5S443S444
   Web of Science ®Google Scholar
• RutgeertsPGeboesKVantrappenGKerremansRCoenegrachtsJLCoremansGNatural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgeryGut19842566656726735250
   PubMed Web of Science ®Google Scholar
• SilversteinMDLoftusEVSandbornWJClinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohortGastroenterology19991171495710381909
   PubMed Web of Science ®Google Scholar
• LichtensteinGRHanauerSBSandbornWJfor the Practice Parameters Committee of the American College of GastroenterologyManagement of Crohn’s disease in adultsAm J Gastroenterol2009104246548319174807
   PubMed Web of Science ®Google Scholar
• CarterMJLoboAJTravisSPGuidelines for the management of inflammatory bowel disease in adultsGut200453Suppl 5V1V1615306569
   PubMed Web of Science ®Google Scholar
• HanauerSBPositioning biologic agents in the treatment of Crohn’s diseaseInflamm Bowel Dis200915101570158219309716
   PubMed Web of Science ®Google Scholar
• KaneSVSchoenfeldPSandbornWJTremaineWHoferTFeaganBGSystematic review: the effectiveness of budesonide therapy for Crohn’s diseaseAliment Pharmacol Ther20021681509151712182751
   PubMed Web of Science ®Google Scholar
• PearsonDCMayGRFickGHSutherlandLRAzathioprine and 6-mercaptopurine in Crohn disease. A meta-analysisAnn Intern Med199512321321427778826
   PubMed Web of Science ®Google Scholar
• SummersRWSwitzDMSessionsJTJrNational Cooperative Crohn’s Disease Study: results of drug treatmentGastroenterology1979774 Pt 284786938176
   PubMed Web of Science ®Google Scholar
• VermeireSVan AsscheGRutgeertsPReview article: altering the natural history of Crohn’s disease – evidence for and against current therapiesAliment Pharmacol Ther200725131217229216
   PubMed Web of Science ®Google Scholar
• FaubionWAJrLoftusEVJrHarmsenWSZinsmeisterARSandbornWJThe natural history of corticosteroid therapy for inflammatory bowel disease: a population-based studyGastroenterology2001121225526011487534
   PubMed Web of Science ®Google Scholar
• CosnesJNion-LarmurierIBeaugerieLAfchainPTiretEGendreJPImpact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgeryGut200554223724115647188
   PubMed Web of Science ®Google Scholar
• DhillonSLLoftusEVTremaineWJThe natural history of surgery for Crohn’s disease in a population-based cohort from Olmsted County, Minnesota [abstract 825]Am J Gastroenterol2005100SupplS305
   Web of Science ®Google Scholar
• CosnesJCattanSBlainALong-term evolution of disease behavior of Crohn’s diseaseInflamm Bowel Dis20028424425012131607
   PubMed Web of Science ®Google Scholar
• Peyrin-BirouletLLoftusEVJrColombelJFSandbornWJThe natural history of adult Crohn’s disease in population-based cohortsAm J Gastroenterol2010105228929719861953
   PubMed Web of Science ®Google Scholar
• MunkholmPLangholzEDavidsenMBinderVDisease activity courses in a regional cohort of Crohn’s disease patientsScand J Gastroenterol19953076997067481535
   PubMed Web of Science ®Google Scholar
• D’HaensGRTop-down therapy for IBD: rationale and requisite evidenceNat Rev Gastroenterol Hepatol201072869220134490
   PubMed Web of Science ®Google Scholar
• SchreiberSReinischWColombelJFEarly Crohn’s disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM [abstract 985]Gastroenterology2007132Suppl 1A147
   Google Scholar
• SandbornWJColombelJFPanesJScholmerichJMcConnellJSchreiberSHigher remission and maintenance of response rates with subcutaneous monthly certolizumab pegol in patients with recent-onset Crohn’s disease: data from PRECiSE 2 [abstract 1109]Am J Gastroenterol2006101S454S455
   Web of Science ®Google Scholar
• SandbornWJRutgeertsPReinischWSONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine in patients with Crohn’s disease naive to immunomodulators and biologic therapy [late-breaking abstract 29]Am J Gastroenterol2008103Suppl 1S423
   Web of Science ®Google Scholar
• D’HaensGBaertFVan AsscheGEarly combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trialLancet2008371961366066718295023
   PubMed Web of Science ®Google Scholar
• MarkowitzJGrancherKKohnNLesserMDaumFA multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s diseaseGastroenterology2000119489590211040176
   PubMed Web of Science ®Google Scholar
• OllendorfDALidskyLInfliximab drug and infusion costs among patients with Crohn’s disease in a commercially-insured settingAm J Ther200613650250617122530
   PubMedGoogle Scholar
• BodgerKEconomic implications of biological therapies for Crohn’s disease: review of infliximabPharmacoeconomics200523987588816153132
   PubMed Web of Science ®Google Scholar
• BeaugerieLSeksikPNion-LarmurierIGendreJPCosnesJPredictors of Crohn’s diseaseGastroenterology2006130365065616530505
   PubMed Web of Science ®Google Scholar
• CosnesJCarbonnelFBeaugerieLLe QuintrecYGendreJPEffects of cigarette smoking on the long-term course of Crohn’s diseaseGastroenterology199611024244318566589
   PubMed Web of Science ®Google Scholar
• CottoneMRosselliMOrlandoASmoking habits and recurrence in Crohn’s diseaseGastroenterology199410636436488119535
   PubMed Web of Science ®Google Scholar
• SandsBEArsenaultJERosenMJRisk of early surgery for Crohn’s disease: implications for early treatment strategiesAm J Gastroenterol200398122712271814687822
   PubMed Web of Science ®Google Scholar
• SilverbergMSSatsangiJAhmadTToward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of GastroenterologyCan J Gastroenterol200519Suppl A53616151544
   PubMed Web of Science ®Google Scholar
• Vernier-MassouilleGBaldeMSalleronJNatural history of pediatric Crohn’s disease: a population-based cohort studyGastroenterology200813541106111318692056
   PubMed Web of Science ®Google Scholar
• BernellOLapidusAHellersGRisk factors for surgery and postoperative recurrence in Crohn’s diseaseAnn Surg20002311384510636100
   PubMed Web of Science ®Google Scholar
• SolbergICVatnMHHoieOClinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up studyClin Gastroenterol Hepatol20075121430143818054751
   PubMed Web of Science ®Google Scholar
• Romberg-CampsMJDagneliePCKesterADInfluence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel diseaseAm J Gastroenterol2009104237138319174787
   PubMed Web of Science ®Google Scholar
• DotanIDisease behavior in adult patients: are there predictors for stricture or fistula formation?Dig Dis200927320621119786742
   PubMed Web of Science ®Google Scholar
• LanghorstJElsenbruchSKoelzerJRuefferAMichalsenADobosGJNoninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indicesAm J Gastroenterol2008103116216917916108
   PubMed Web of Science ®Google Scholar
• SipponenTSavilahtiEKärkkäinenPFecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s diseaseInflamm Bowel Dis200814101392139818484671
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGStoinovSCertolizumab pegol for the treatment of Crohn’s diseaseN Engl J Med2007357322823817634458
   PubMed Web of Science ®Google Scholar
• HenriksenMJahnsenJLygrenIC-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based studyGut200857111518152318566104
   PubMed Web of Science ®Google Scholar
• SchoepferAMTrummlerMSeeholzerPSeibold-SchmidBSeiboldFDiscriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodiesInflamm Bowel Dis2008141323917924558
   PubMed Web of Science ®Google Scholar
• SipponenTSavilahtiEKolhoKLNuutinenHTurunenUFarkkilaMCrohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findingsInflamm Bowel Dis2008141404618022866
   PubMed Web of Science ®Google Scholar
• SaxonAShanahanFLandersCGanzTTarganSA distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel diseaseJ Allergy Clin Immunol19908622022102200820
   PubMed Web of Science ®Google Scholar
• MainJMcKenzieHYeamanGRAntibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s diseaseBMJ19882976656110511063143445
   PubMed Web of Science ®Google Scholar
• Peyrin-BirouletLStandaert-VitseABrancheJChamaillardMIBD serological panels: facts and perspectivesInflamm Bowel Dis200713121561156617636565
   PubMed Web of Science ®Google Scholar
• PapoMQuerJCPastorRMAntineutrophil cytoplasmic antibodies in relatives of patients with inflammatory bowel diseaseAm J Gastroenterol1996918151215158759652
   PubMed Web of Science ®Google Scholar
• FolwacznyCNoehlNEndresSPLoeschkeKFrickeHAnti-neutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel diseaseScand J Gastroenterol19983355235289648993
   PubMed Web of Science ®Google Scholar
• VasiliauskasEAPlevySELandersCJPerinuclear antineutrophil cytoplasmic antibodies in patients with Crohn’s disease define a clinical subgroupGastroenterology19961106181018198964407
   PubMed Web of Science ®Google Scholar
• SendidBQuintonJFCharrierGAnti-Saccharomyces cerevisiae mannan antibodies in familial Crohn’s diseaseAm J Gastroenterol1998938130613109707056
   PubMed Web of Science ®Google Scholar
• VermeireSPeetersMVlietinckRAnti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD familiesInflamm Bowel Dis20017181511233666
   PubMed Web of Science ®Google Scholar
• SuttonCLKimJYamaneAIdentification of a novel bacterial sequence associated with Crohn’s diseaseGastroenterology20001191233110889151
   PubMed Web of Science ®Google Scholar
• HalfvarsonJStandaert-VitseAJarnerotGAnti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel diseaseGut20055491237124315863472
   PubMed Web of Science ®Google Scholar
• SeiboldFKonradAFlogerziBGenetic variants of the mannan-binding lectin are associated with immune reactivity to mannans in Crohn’s diseaseGastroenterology200412741076108415480986
   PubMed Web of Science ®Google Scholar
• MullerSSchafferTFlogerziBMannan-binding lectin deficiency results in unusual antibody production and excessive experimental colitis in response to mannose-expressing mild gut pathogensGut201059111493150020682699
   PubMed Web of Science ®Google Scholar
• MeiLTarganSRLandersCJFamilial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn’s diseaseGastroenterology200613041078108516618402
   PubMed Web of Science ®Google Scholar
• TorokHPGlasJHollayHCSerum antibodies in first-degree relatives of patients with IBD: a marker of disease susceptibility? A follow-up pilot-study after 7 yearsDigestion2005722–311912316172548
   PubMed Web of Science ®Google Scholar
• IsraeliEGrottoIGilburdBAnti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel diseaseGut20055491232123616099791
   PubMed Web of Science ®Google Scholar
• Standaert-VitseAJouaultTVandewallePCandida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn’s diseaseGastroenterology200613061764177516697740
   PubMed Web of Science ®Google Scholar
• BerlinTZandman-GoddardGBlankMAutoantibodies in nonautoimmune individuals during infectionsAnn N Y Acad Sci2007110858459317894023
   PubMed Web of Science ®Google Scholar
• CondinoAAHoffenbergEJAccursoFFrequency of ASCA seropositivity in children with cystic fibrosisJ Pediatr Gastroenterol Nurs20054112326
   Web of Science ®Google Scholar
• LachenalFNkanaKNove-JosserandRFabienNDurieuIPrevalence and clinical significance of auto-antibodies in adults with cystic fibrosisEur Respir J20093451079108519443536
   PubMed Web of Science ®Google Scholar
• MakhariaGKSachdevVGuptaRLalSPandeyRMAnti-Saccharomyces cerevisiae antibody does not differentiate between Crohn’s disease and intestinal tuberculosisDig Dis Sci2007521333917160471
   PubMed Web of Science ®Google Scholar
• GranitoAZauliDMuratoriPAnti-Saccharomyces cerevisiae and perinuclear antineutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free dietAliment Pharmacol Ther200521788188715801923
   PubMed Web of Science ®Google Scholar
• SaklyWMankaiASaklyNAnti-Saccharomyces cerevisiae antibodies are frequent in type 1 diabetesEndocr Pathol201021210811420387011
   PubMed Web of Science ®Google Scholar
• MuratoriPMuratoriLGuidiMAnti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseasesClin Exp Immunol2003132347347612780695
   PubMed Web of Science ®Google Scholar
• RienteLChimentiDPratesiFAntibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritisJ Rheumatol200431592092415124251
   PubMed Web of Science ®Google Scholar
• SendidBColombelJFJacquinotPMSpecific antibody response to oligomannosidic epitopes in Crohn’s diseaseClin Diagn Lab Immunol1996322192268991640
   PubMedGoogle Scholar
• Standaert-VitseASendidBJoossensMCandida albicans colonization and ASCA in familial Crohn’s diseaseAm J Gastroenterol200910471745175319471251
   PubMed Web of Science ®Google Scholar
• AnandBSDiagnosis of gastrointestinal tuberculosisTrop Gastroenterol19941541791857618199
   PubMedGoogle Scholar
• HoffmanIEDemetterPPeetersMAnti-Saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathyAnn Rheum Dis200362545545912695160
   PubMed Web of Science ®Google Scholar
• ZauliDGhettiSGrassiAAnti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitisHepatology1997255110511079141425
   PubMed Web of Science ®Google Scholar
• MowWSVasiliauskasEALinYCAssociation of antibody responses to microbial antigens and complications of small bowel Crohn’s diseaseGastroenterology2004126241442414762777
   PubMed Web of Science ®Google Scholar
• ArnottIDLandersCJNimmoEJSero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotypeAm J Gastroenterol200499122376238415571586
   PubMed Web of Science ®Google Scholar
• PapadakisKAYangHIppolitiAAnti-flagellin (CBir1) phenotypic and genetic Crohn’s disease associationsInflamm Bowel Dis200713552453017260364
   PubMed Web of Science ®Google Scholar
• DubinskyMCLinYCDutridgeDSerum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progressionAm J Gastroenterol2006101236036716454844
   PubMed Web of Science ®Google Scholar
• DubinskyMCKugathasanSMeiLIncreased immune reactivity predicts aggressive complicating Crohn’s disease in childrenClin Gastroenterol Hepatol20086101105111118619921
   PubMed Web of Science ®Google Scholar
• IppolitiADevlinSMeiLCombination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn’s diseaseInflamm Bowel Dis20101681279128520027650
   PubMed Web of Science ®Google Scholar
• SandbornWJLoftusEVJrColombelJFEvaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn’s diseaseInflamm Bowel Dis20017319220111515844
   PubMed Web of Science ®Google Scholar
• PeetersMJoossensSVermeireSVlietinckRBossuytXRutgeertsPDiagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseaseAm J Gastroenterol200196373073411280542
   PubMed Web of Science ®Google Scholar
• KleblFHBatailleFHofstadterFHerfarthHScholmerichJRoglerGOptimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn’s diseaseInt J Colorectal Dis200419431932414745572
   PubMed Web of Science ®Google Scholar
• ReeseGEConstantinidesVASimillisCDiagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel diseaseAm J Gastroenterol2006101102410242216952282
   PubMed Web of Science ®Google Scholar
• SolbergICLygrenICvancarovaMPredictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel diseaseInflamm Bowel Dis200915340641419009607
   PubMed Web of Science ®Google Scholar
• FerranteMHenckaertsLJoossensMNew serological markers in inflammatory bowel disease are associated with complicated disease behaviourGut200756101394140317456509
   PubMed Web of Science ®Google Scholar
• AshornSHonkanenTKolhoKLFecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel diseaseInflamm Bowel Dis200915219920518618670
   PubMed Web of Science ®Google Scholar
• BenorSRussellGHSilverMIsraelEJYuanQWinterHSShortcomings of the Inflammatory Bowel Disease Serology 7 panelPediatrics201012561230123620439597
   PubMed Web of Science ®Google Scholar
• MorgansternJAShakirTChawlaAIs CBir1 a predictor of pediatric inflammatory bowel disease? [abstract 2]J Pediatr Gastroenterol Nutr200745E1
   Google Scholar
• RashidFBechtoldMLPuliSRBraggJDUtility of IBD serology tests: experience of an academic medical centerThe Internet J Gastroenterol2011101
   Google Scholar
• LandersCJCohavyOMisraRSelected loss of tolerance evidenced by Crohn’s disease-associated immune responses to auto- and microbial antigensGastroenterology2002123368969912198693
   PubMed Web of Science ®Google Scholar
• LodesMJCongYElsonCOBacterial flagellin is a dominant antigen in Crohn diseaseJ Clin Invest200411391296130615124021
   PubMed Web of Science ®Google Scholar
• TarganSRLandersCJYangHAntibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s diseaseGastroenterology200512872020202815940634
   PubMed Web of Science ®Google Scholar
• DotanIFishmanSDganiYAntibodies against laminaribioside and chitobioside are novel serologic markers in Crohn’s diseaseGastroenterology2006131236637816890590
   PubMed Web of Science ®Google Scholar
• JoossensSReinischWVermeireSThe value of serologic markers in indeterminate colitis: a prospective follow-up studyGastroenterology200212251242124711984510
   PubMed Web of Science ®Google Scholar
• ForcioneDGRosenMJKisielJBSandsBEAnti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn’s diseaseGut20045381117112215247177
   PubMed Web of Science ®Google Scholar
• KleblFHBatailleFBerteaCRAssociation of perinuclear anti-neutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn’s diseaseInflamm Bowel Dis20039530230714555913
   PubMed Web of Science ®Google Scholar
• VasiliauskasEAKamLYKarpLCGaiennieJYangHTarganSRMarker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristicsGut200047448749610986208
   PubMed Web of Science ®Google Scholar
• FleshnerPRVasiliauskasEAKamLYHigh level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosisGut200149567167711600470
   PubMed Web of Science ®Google Scholar
• FleshnerPIppolitiADubinskyMBoth preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosisClin Gastroenterol Hepatol20086556156818378498
   PubMed Web of Science ®Google Scholar
• AbreuMTTaylorKDLinYCMutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s diseaseGastroenterology2002123367968812198692
   PubMed Web of Science ®Google Scholar
• BrantSRPiccoMFAchkarJPDefining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn’s disease phenotypesInflamm Bowel Dis20039528128914555911
   PubMed Web of Science ®Google Scholar
• SchoepferAMSchafferTMuellerSPhenotypic associations of Crohn’s disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss CohortInflamm Bowel Dis20091591358136719253375
   PubMed Web of Science ®Google Scholar
• LesageSZoualiHCezardJPCARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel diseaseAm J Hum Genet200270484585711875755
   PubMed Web of Science ®Google Scholar
• IppolitiAFDevlinSYangHThe relationship between abnormal innate and adaptive immune function and fibrostenosis in Crohn’s disease patients [abstract 127]Gastroenterology2006130A24A25
   Web of Science ®Google Scholar
• HugotJPChamaillardMZoualiHAssociation of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s diseaseNature2001411683759960311385576
   PubMed Web of Science ®Google Scholar
• OguraYBonenDKInoharaNA frameshift mutation in NOD2 associated with susceptibility to Crohn’s diseaseNature2001411683760360611385577
   PubMed Web of Science ®Google Scholar
• FrankeAMcGovernDPBarrettJCGenome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility lociNat Genet201042121118112521102463
   PubMed Web of Science ®Google Scholar
• EconomouMTrikalinosTALoizouKTTsianosEVIoannidisJPDifferential effects of NOD2 variants on Crohn’s disease risk and phenotype in diverse populations: a metaanalysisAm J Gastroenterol200499122393240415571588
   PubMed Web of Science ®Google Scholar
• YazdanyarSKamstrupPRTybjaerg-HansenANordestgaardBGPenetrance of NOD2/CARD15 genetic variants in the general populationCMAJ2010182766166520371648
   PubMed Web of Science ®Google Scholar
• HelioTHalmeLLappalainenMCARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn’s diseaseGut200352455856212631669
   PubMed Web of Science ®Google Scholar
• AhmadTArmuzziABunceMThe molecular classification of the clinical manifestations of Crohn’s diseaseGastroenterology2002122485486611910336
   PubMed Web of Science ®Google Scholar
• WeersmaRKStokkersPCvan BodegravenAAMolecular prediction of disease risk and severity in a large Dutch Crohn’s disease cohortGut200958338839518824555
   PubMed Web of Science ®Google Scholar
• DassopoulosTFrangakisCCruz-CorreaMAntibodies to Saccharomyces cerevisiae in Crohn’s disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated diseaseInflamm Bowel Dis200713214315117206688
   PubMed Web of Science ®Google Scholar
• DevlinSMYangHIppolitiANOD2 variants and antibody response to microbial antigens in Crohn’s disease patients and their unaffected relativesGastroenterology2007132257658617258734
   PubMed Web of Science ®Google Scholar
• JoossensMVan SteenKBrancheJFamilial aggregation and antimicrobial response dose-dependently affect the risk for Crohn’s diseaseInflamm Bowel Dis2010161586719504613
   PubMed Web of Science ®Google Scholar
• TakedatsuHTaylorKDMeiLLinkage of Crohn’s disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activationGut2009581606718832525
   PubMed Web of Science ®Google Scholar
• WalkerLJAldhousMCDrummondHEAnti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn’s disease are associated with disease severity but not NOD2/CARD15 mutationsClin Exp Immunol2004135349049615008984
   PubMed Web of Science ®Google Scholar
• LichtensteinGRBarkenDMEgglestonLA novel algorithm-based approach using clinical parameters, genetic and serological markers to effectively predict aggressive disease behavior in patients with Crohn’s disease [abstract 207]Presented at Digestive Disease WeekNew Orleans, LAMay 1–6, 2010
   Google Scholar
• ArnottIDMcNeillGSatsangiJAn analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn’s diseaseAliment Pharmacol Ther200317121451145712823146
   PubMed Web of Science ®Google Scholar
• MaserEAVillelaRSilverbergMSGreenbergGRAssociation of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s diseaseClin Gastroenterol Hepatol20064101248125416931170
   PubMed Web of Science ®Google Scholar
• SandbornWJLandersCJTremaineWJTarganSRAssociation of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot studyMayo Clin Proc19967154314368628021
   PubMed Web of Science ®Google Scholar
• MowWSLandersCJSteinhartAHHigh-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn’s disease: a pilot studyDig Dis Sci2004497–81280128615387358
   PubMed Web of Science ®Google Scholar
• EstersNVermeireSJoossensSSerological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s diseaseAm J Gastroenterol20029761458146212094865
   PubMed Web of Science ®Google Scholar
• FerranteMVermeireSKatsanosKHPredictors of early response to infliximab in patients with ulcerative colitisInflamm Bowel Dis200713212312817206703
   PubMed Web of Science ®Google Scholar
• HlavatyTFerranteMHenckaertsLPierikMRutgeertsPVermeireSPredictive model for the outcome of infliximab therapy in Crohn’s disease based on apoptotic pharmacogenetic index and clinical predictorsInflamm Bowel Dis200713437237917206723
   PubMed Web of Science ®Google Scholar
• DubinskyMCMeiLFriedmanMGenome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel diseaseInflamm Bowel Dis20091681357136620014019
   PubMed Web of Science ®Google Scholar
• DevlinSMDubinskyMCDetermination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBDInflamm Bowel Dis200814112512817932968
   PubMed Web of Science ®Google Scholar